Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

99.08 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years
Via Benzinga
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations
Via Benzinga
Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories
Benzinga 
Via Benzinga
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues
Last week the FDA said Novartis AG's (NYSE: NVS) Pluvicto is short in supply due to manufacturing and delivery issues.  Pluvicto is a radiopharmaceutical medication used for prostate-specific membrane... 
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
Exposures Product Safety
This High-Yielding Blue Chip Stock Is a Strong Buy
This big pharma company pays a market-topping dividend to shareholders. 
Via The Motley Fool
3 High Dividend Stocks With Attractive Total Return Potential
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns. 
Via InvestorPlace
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
Top CRISPR Stocks
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
4 AI Stocks That Are Revolutionizing Healthcare
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry. 
Via InvestorPlace
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field. 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Via Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
Lupus Therapeutics Market Is on the Verge of Crossing at High CAGR of 9% in 2022-2029
The global lupus therapeutics market is expected to reach a CAGR of 9% during the forecast period (2022-2029). 
Via SBWire
Bladder Prolapse (Cystocele) Market to Touch at High CAGR of 8.3% by 2022-2029
Bladder Prolapse (cystocele) Market is expected to grow at a CAGR of 8.3 % during the forecast period (2022-2029). 
Via SBWire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer... 
Via SBWire
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029). 
Via SBWire
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Via Benzinga
Water for Injection Market Trends Outlook Demand 2023 -2030
Global Water for Injection Market to Witness Huge Growth by Key Players: Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International... 
Via SBWire
Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
Enterprise software maker Snowflake notched a three-month gain of 28.85%, far outpacing the S&P 500’s return of 9.32%. Analysts expect the price to rise 19%. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
Active Pharmaceutical Ingredients Market May Set Epic Growth Story : Pfizer, Novartis, Sanofi
Stay up-to-date with Active Pharmaceutical Ingredients Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Death
Exposures Death
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG 
Via SBWire
Exposures COVID-19
Shigella Vaccines Market: Study Navigating the Future Growth Outlook
Get Shigella Vaccines Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.